(Top) Melanoma develops resistance to BRAF inhibitors, leading to cancer recurrence. (Bottom) By combining polyamine biosynthesis inhibition with BRAF inhibitors, the recurrence of cancer can be ...

Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations ...

BRAF V600E-mutant metastatic CRC is associated with poor clinical outcomes, with a median overall survival of 17 months. Factors influencing overall survival include metastasectomy and ECOG ...

Hairy-cell leukemia (HCL) is a rare, indolent neoplasm of mature B cells with hairlike surface projections that circulate in the blood and preferentially infiltrate the bone marrow and spleen. The ...

Raf kinases are components of the MAP kinase pathway, a signal transduc-tion pathway that normally controls cell growth and division downstream of activated cell surface growth factor receptors. RAF1, ...

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...

Pattern and predictors of D3 lymph node station positivity in patients undergoing curative surgery for adenocarcinoma of colon. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal ...

Nurix Therapeutics, Inc. presented promising preclinical data at the AACR 2025 Annual Meeting, showcasing their innovative targeted protein degradation medicines aimed at addressing various cancers, ...

Amivantamab targets EGFR and MET receptors, offering a novel approach for mCRC treatment, especially in RAS and BRAF wild-type patients. The OrigAMI-2 study compares amivantamab with standard ...